Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
BRIDGEWATER, N.J., May 01, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 4:10 p.m. EDT.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
[email protected]
